Cell and gene therapies help regulate, repair, replace, or enhance the functioning of cells or tissues in the body. Cell therapies involve stimulating one's own cells or tissues to treat disease, while gene therapies transfer genes into one's cells to treat or prevent disease. The rising prevalence of cancer and chronic diseases have increased the demand for cell and gene therapies over the past decade. Therapies that genetically alter T-cells to fight off cancer cells have shown promising results in clinical trials. Immunotherapy using modified cell and gene therapies helps improve patient outcomes and extends survival rates.
Market key trends:
Emerging cell and gene therapies for cancer treatment is a key trend driving market growth. Chimeric antigen receptor (CAR) T-cell therapies have shown durable clinical responses and prolonged survival in clinical trials of patients with hematologic cancers. Companies are developing CAR T-cell therapies targeting solid tumors which could expand the use of these personalized immunotherapies for cancers like lung, breast and prostate cancers. Other adoptive cell therapies using modified natural killer cells or tumor-infiltrating lymphocytes are also being evaluated. Gene therapies are also emerging for various cancer types. Companies are conducting clinical trials of therapies that genetically modify T-cells or hematopoietic stem cells with cancer-fighting genes. The success of these novel therapeutic approaches could significantly increase the adoption of cell and gene therapies as an alternative or addition to traditional cancer treatment modalities.
Segment Analysis
The global cell and gene therapy market is dominated by the oncology sub segment. Around 48% of the clinical trials registered are related to cancer therapy as it has wide scope of cell and gene based treatment options. Conditions like leukemia, lymphoma have received regulatory approvals for cell therapies. Various autologous and allogeneic cell therapies are in pipeline and clinical trials for solid tumors which is anticipated to boost the oncology sub segment growth over forecast period.
Key Takeaways
The Global Cell And Gene Therapy Market Demand is expected to witness high growth over the forecast period of 2024 to 2031. The global Cell and Gene Therapy Market is estimated to be valued at US$ 21.08 billion in 2024 and is expected to exhibit a CAGR of 19.4% over the forecast period 2024-2031.
Regional analysis shows that North America dominated the market with around 35% share in 2024 due to presence of advanced research infrastructure and streamlined regulatory approval pathway for cell and gene therapies. The Asia Pacific region is expected to witness fastest growth over forecast period due to increasing healthcare expenditure, rising disposable income, developing research infrastructure and growing focus of key players in the region.
Key players operating in the cell and gene therapy market are Tadano Ltd, Liebherr Group, Terex Corporation, Xuzhou Construction Machinery Group Co., Ltd, Sany Heavy Industry Co. Ltd, Zoomlion Heavy Industry Science and Technology Co., Kobelco Construction Machinery Co., Ltd, Manitowoc Cranes, Link-Belt Cranes, Kato Works Co. Ltd, Palfinger AG. The leading players are focusing on new product launches, collaborations and geographical expansion strategies to strengthen their market position. For instance, in 2023, Tadano Ltd launched new all terrain crane TZ234AT-8L with 34 ton lifting capacity to expand its product portfolio.
Explore more information on this topic, Please visit -
https://www.trendingwebwire.com/cell-and-gene-therapy-market-size-and-trends-analysis/
Comments
0 comment